BrainStorm Hoping For Advisory Committee After FDA Refuses To File BLA For Its ALS Cell Therapy

BrainStorm, which has a history of antagonizing FDA with direct appeals to patients for NurOwn, tells investors that public elements of an adcomm could be ‘persuasive,’ but first step will be formal meeting request to try to overcome the RTF. Firm sees Relyvrio as template for success.

ALS neurons
A confirmatory trial is one possibility that BrainStorm will discuss with the FDA following NurOwn's refuse-to-file letter. • Source: Shutterstock

BrainStorm Cell Therapeutics Inc. is hoping a US Food and Drug Administration advisory committee meeting can save its ALS cell therapy candidate NurOwn (autologous MSC-NTF cells) after the application received a refuse-to-file action.

NurOwn uses stem cells to deliver neurotrophic factors and immunomodulatory cytokines directly to the site of damage to slow or...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approval Standards

Cancer Patient-Reported Outcomes Find Fertile Ground In GVHD, Myelofibrosis Labeling

 

The FDA reviewed its efforts to bring PROs into cancer drug development at its 10th annual workshop on clinical outcome assessment in cancer trials.

US FDA Guidances Tread Lightly On Trial Population Language

 

The Trump Administration’s anti-DEI rhetoric does not appear to have dramatically impacted US FDA communications in guidance about assuring representative patient populations.

Cell & Gene Therapies: US FDA Broadens Acceptable Use of RWD, Registries and AI

 
• By 

The guidance on post-market surveillance is one among a trio of new guidelines related to cell and gene therapies in the post-Peter Marks era.

Patient Experience Data: US FDA Wants To Know What’s Coming In An Application And Why

 
• By 

Reviewers often cannot locate patient experience data, such as clinical outcome assessments and focus group transcripts, in an application or are not clear on why the sponsor expects these data to support a regulatory decision, FDA’s Robyn Bent told the RAPS Convergence 2025 meeting.

More from Pathways & Standards

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal

 
• By 

A combination of two individual IVF treatments, Pergoveris has the potential to be a lower cost option in the US, one of the qualifications the FDA wants in a National Commissioner's Priority Voucher candidate.